Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that novel androgen antagonists incorporating a carborane moiety showed anti-androgenic activity comparable to flutamide in a laboratory setting.

This study suggests that stress-associated hair loss may occur due to increased androgen receptor expression and activity induced by dexamethasone in human and mouse dermal papilla cells.

This study identified novel 4-Amino-2H-benzo[h]chromen-2-one analogs as potent androgen receptor antagonists that show strong antiproliferative activity against prostate cancer cells, suggesting them as potential lead compounds for therapy development.

Two new compounds can block androgen receptor activity in different ways and may lead to new treatments for androgen-related diseases.

This study found that the optimized AR antagonist compound 39 showed potent hair growth activity with improved safety in mice, suggesting potential for better topical treatments for androgenetic alopecia.

This study evaluated novel steroids' potential as future hormonal therapies for neuroprotection in glucose disorders, but emphasized that further research is needed to optimize androgen antagonist use in the context of COVID-19 progression.

This study found that dutasteride more effectively inhibited androgen receptor signaling and reduced cell growth compared to finasteride in prostate cancer cell models, with varying sensitivities across different cell lines.

This study identified pantolactam based compounds as effective topical antagonists of the androgen receptor, reducing sebum components in a hamster model.

This study identified compounds 11d and 11k as potential dual 5α-reductase inhibitors and AR antagonists with significant anti-proliferative effects on prostate cancer cell lines, suggesting they may offer therapeutic value.

This study found that in adolescent male rats, androgens enhance inhibitory avoidance memory, possibly by interacting with androgen receptors in the amygdala and hippocampus.

This review discusses AR-modulating agents developed between 2012 and 2018, highlighting challenges with ligand-binding domain antagonists and proposing nonconventional approaches targeting other domains as promising strategies.

This discussion proposes a model to incorporate patients with hormone-resistant prostate cancer into the existing framework by redefining hormone resistance and exploring new therapeutic approaches.

This study found that finasteride decreased DHT-stimulated AR activity and cell growth in prostate cancer cells with mutant AR, but not in those with wild type AR.

This review discusses three classes of thiazole-bearing compounds in drug development and presents preclinical findings but reports no new experimental results, highlighting the need for further drug discovery.

This study concluded that mixtures of weak endocrine disruptors, such as parabens and azole fungicides, can produce combination effects that should be considered in regulatory risk assessments to avoid underestimating potential risks.

This article reviews guidelines and medications for treating benign prostatic hyperplasia but presents no new clinical results.

The Androgen Receptor could be a target for treating diseases like cancer, but more research is needed to confirm the effectiveness of potential treatments.

This study found that several preservatives, including triclocarban and triclosan, showed potential endocrine-disrupting effects on various nuclear receptors in both in silico and in vitro models.

This review discusses the use of antiandrogens like flutamide and its derivatives in prostate cancer treatment and highlights the need for next-generation antiandrogens for improved efficacy; it reports no new clinical results.

In this study, a novel mutation in the glucocorticoid receptor gene was identified in a young woman, impairing glucocorticoid signaling and leading to generalized glucocorticoid resistance.

This article discusses the role of the androgen receptor in regulating development and homeostasis, and reviews treatment approaches for conditions related to hormone imbalances, without reporting new clinical findings.

This study found that hair products commonly used by Black women exhibited hormonal activity, which could impact health outcomes and contribute to health disparities.

This study identified novel selective androgen receptor modulators with enhanced in vivo pharmacological activity through structure-activity relationship analysis in castrated rats.

This study found that topical finasteride and flutamide both significantly reduced sebaceous gland growth and decreased prostatic weights in hamsters, indicating systemic effects despite local application.

This study found that hypaphorine alters cytoskeletal organization in Eucalyptus globulus root hairs, contributing to reduced root hair elongation by possibly disrupting vesicle delivery needed for growth.

In this study, researchers examined androgen receptor activity in the adult mouse brain and found specific expression in key brain areas, which could inform understanding of cognitive side effects in humans undergoing androgen deprivation therapy for prostate cancer.

In this study, HA-P5, a nanoparticle derived from peptide and polysaccharide conjugation, effectively reduced acne lesions and sebum production by inhibiting specific receptors in cells, without triggering unfavorable reactions compared to a commercial inhibitor, highlighting HA-P5's potential as a novel acne treatment.

This review discusses common skin eruptions caused by biologics in treating inflammatory bowel disease and proposes tailored therapeutic approaches for managing these adverse reactions.

This review discusses the structure, expression, regulation, and potential roles of NcoA4 in cancer and other pathologies, reporting no new experimental findings.

This study found that AR/VDR-targeted agonist hormone therapy can inhibit cell viability in HR2-av triple-negative breast cancer cell lines through multiple mechanisms and may enhance the effects of chemotherapy.